- Title:
- P272 NMD670, a novel first-in-class muscle ClC-1 inhibitor, improves symptoms of myasthenia gravis: a randomized, single-dose, double-blind, placebo-controlled study
- Authors:
- Source:
- In Neuromuscular Disorders October 2023 33 Supplement 1:S178-S178
Academic Journal